Cancer development is driven by the accumulation of alterations affecting the structure and
function of the genome. Whereas genetic changes disrupt the DNA sequence, epigenetic …

This Seminar presents the current best practice for the diagnosis and management of
bladder cancer. The scope of this Seminar ranges from current challenges in pathology …

Background and objective This publication represents a summary of the updated 2024
European Association of Urology (EAU) guidelines for non–muscle-invasive bladder cancer …

Simple Summary The clinical management of bladder cancer has been developing in the
past decade, including diagnostic tools and treatment options. Both monotherapy and …

PURPOSE There is a significant unmet need for new and efficacious therapies in urothelial
cancer (UC). To provide recommendations on appropriate clinical trial designs across …

Bladder cancer (BC) is the 10th most frequent cancer in the world. The initial diagnosis and
surveillance of BC require a combination of invasive and non-invasive methods, which are …

Background. There is accumulating evidence that the lymphocyte‐to‐monocyte ratio (LMR)
is related to the outcomes of cancer patients treated with immune checkpoint inhibitors …

Simple Summary Bladder cancer (BC) is a common cancer that causes high morbidity and
mortality among affected patients. As a carcinogen-driven cancer, molecular oncology of BC …

Bladder cancer is a common urinary tract cancer with a difficult clinical course. With frequent
recurrence, patients with a history of bladder cancer often undergo surveillance that involves …

Simple Summary The clinical utility of urine nectins in bladder cancer (BCa) is unclear. We
investigated the potential diagnostic and prognostic values of Nectin-2 and Nectin-4. This …